Moxifloxacin

Generic Name: Moxifloxacin

Brand Names: Avelox, Moxeza, Vigamox

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₄FN_₃O_₄

CAS Number: 151096-09-2

Unique Ingredient Identifier: U188XYD42P

Background: Moxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.

Indication: For the treatment of sinus and lung infections such as sinusitis, pneumonia, and secondary infections in chronic bronchitis. Also for the treatment of bacterial conjunctivitis (pinkeye).

Associated Conditions: Acute Exacerbation of Chronic Bronchitis (AECB), Bacterial Conjunctivitis, Community Acquired Pneumonia (CAP), Plague, Postoperative Infections, Postoperative Inflammatory Response, Sinusitis, Skin Infections, Ocular bacterial infections

Associated Therapies: -

Clinical Trials

Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: ALS-008176
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2016-07-14

Last Posted Date: 2017-09-18

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 103

Registration Number: NCT02833831

Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Domperidone
Drug: Placebo
Drug: Moxifloxacin

First Posted Date: 2016-06-29

Last Posted Date: 2016-11-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 44

Registration Number: NCT02816853

Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia

Phase 3

Completed

Conditions: Community Acquired Pneumonia

Interventions: Drug: Moxifloxacin
Drug: lefamulin

First Posted Date: 2016-06-27

Last Posted Date: 2019-10-23

Lead Sponsor: Nabriva Therapeutics AG

Target Recruit Count: 738

Registration Number: NCT02813694

Locations: 🇺🇸
Site 1060, Houston, Texas, United States
🇺🇸
Site 1065, Fresno, California, United States
🇺🇸
Site 1069, Houston, Texas, United States

and more 152 locations

Vancomycin Plus Moxifloxacin Versus Vancomycin Plus Ceftazidime for the Treatment of Peritoneal Dialysis (PD)-Related Peritonitis

Not Applicable

Completed

Conditions: Peritoneal Dialysis Associated Peritonitis

Interventions: Drug: vancomycin
Drug: ceftazidime
Drug: moxifloxacin

First Posted Date: 2016-06-01

Last Posted Date: 2020-03-26

Lead Sponsor: Peking University First Hospital

Target Recruit Count: 80

Registration Number: NCT02787057

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: PF-04447943
Drug: Moxifloxacin

First Posted Date: 2016-05-30

Last Posted Date: 2018-12-28

Lead Sponsor: Pfizer

Target Recruit Count: 44

Registration Number: NCT02785770

Locations: 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States

Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.

Phase 3

Terminated

Conditions: Endophthalmitis

Interventions: Drug: No injection of moxifloxacin
Drug: Moxifloxacin

First Posted Date: 2016-05-12

Last Posted Date: 2018-08-21

Lead Sponsor: University of Campinas, Brazil

Target Recruit Count: 3640

Registration Number: NCT02770729

Locations: 🇧🇷
Mathias Violante Mélega, Campinas, São Paulo, Brazil

Evaluating Newly Approved Drugs for Multidrug-resistant TB

Phase 3

Completed

Conditions: Tuberculosis, Multidrug-Resistant
Infection, Bacterial
Pulmonary Tuberculoses

Interventions: Drug: Control arm MDR-TB regimen, consistent with WHO guidelines
Drug: Bedaquiline
Drug: Clofazimine
Drug: Delamanid
Drug: Moxifloxacin
Drug: Linezolid
Drug: Levofloxacin
Drug: Pyrazinamide

First Posted Date: 2016-04-28

Last Posted Date: 2024-07-24

Lead Sponsor: Médecins Sans Frontières, France

Target Recruit Count: 754

Registration Number: NCT02754765

Locations: 🇵🇪
Hospital Nacional Dos de Mayo Parque Historia de la Medicina, Lima, Peru
🇰🇿
National Center for Tuberculosis Problems, Almaty, Kazakhstan
🇬🇪
National Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia

and more 9 locations

A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Intranasal Esketamine
Drug: Intravenous Esketamine
Drug: Moxifloxacin
Drug: Oral Placebo
Drug: Intravenous Placebo
Drug: Intranasal Placebo

First Posted Date: 2016-04-14

Last Posted Date: 2018-04-11

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 62

Registration Number: NCT02737605

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Phase 1

Completed

Conditions: Heart Repolarization

Interventions: Drug: Naltrexone HCl/bupropion HCl
Other: Placebo
Drug: Moxifloxacin

First Posted Date: 2016-04-12

Last Posted Date: 2016-11-01

Lead Sponsor: Orexigen Therapeutics, Inc

Target Recruit Count: 84

Registration Number: NCT02735603

Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome

Not Applicable

Completed

Conditions: Long QT Syndrome

Interventions: Drug: Moxifloxacin
Dietary Supplement: Grapefruit group

First Posted Date: 2016-02-11

Last Posted Date: 2019-05-24

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 25

Registration Number: NCT02680080

Locations: 🇮🇱
Sourasky medical center (Ichilov), Tel-Aviv, Israel

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy